Filters
Adolescents with self-induced vomiting appear to have a higher likelihood of subsequent endometriosis diagnosis, whereas those with binge eating have a lower likelihood, as shown in a study.
A substantial proportion of children with interstitial lung diseases are malnourished, which is negatively associated with lung function and disease severity, according to a study.
Adding nipocalimab to standard-of-care (SoC) demonstrates sustained disease control through week 120 in adult patients with antibody-positive generalized myasthenia gravis (gMG), including anti-AChR* or anti-MuSK**, according to the Vivacity-MG3 open-label extension (OLE) study presented at AAN 2026.
In pregnant women exposed to antiseizure medications (ASMs), supplementation with folic acid helps lower the risk of adverse offspring outcomes, according to a study.
Treatment with either dose of linaclotide (72 or 145 µg) showed improves bowel movement frequency and abdominal symptoms in adults with severe chronic idiopathic constipation (CIC), according to a post hoc pooled analysis of phase III studies presented at DDW 2026.
Eating-related behaviours among adolescents are significantly associated with body composition, with variations across domains and by sex, suggests a study.
Treatment with levacetylleucine significantly improves ataxia symptoms in paediatric and adult patients with ataxia-telangiectasia (A-T) compared with placebo, according to the phase III IB1001-303 trial presented at AAN 2026.
The investigational allogeneic cell therapy deramiocel helps mitigate the progression of upper limb disease in young patients with Duchenne muscular dystrophy (DMD), as shown in the pivotal phase 3 HOPE-3 study.
A combination of early allergic conditions, delayed allergen introduction, genetics, antibiotic exposure, demographic factors, and birth-related variables factor in the development of food allergy in children, according to a meta-analysis.
New drug applications approved by US FDA as of 16-30 April 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
